Journal Article

DZNE-2020-06199

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.

Schrempf, W. ; Fauser, M. ; Wienecke, M. ; Brown, S. ; Maaß, A. ; Ossig, C. ; Otto, K. ; Brandt, M. D. ; Löhle, M.DZNE* ; Schwanebeck, U. ; Graehlert, X. ; Reichmann, H. ; Storch, A. (Last author)DZNE*

2018
Blackwell Science78889 Oxford

This record in other databases:    

Please use a persistent id in citations: doi:10.1111/ene.13567

Abstract: The aim was to study the effects of rasagiline on sleep quality in patients with Parkinson's disease (PD) with sleep disturbances. Sleep disorders are common in PD. Rasagiline is widely used in patients with PD, but double-blind polysomnographic trials on its effects on sleep disturbances are missing.This was a single-center, double-blind, baseline-controlled investigator-initiated clinical trial of rasagiline (1 mg/day) over 8 weeks in patients with PD with sleep disturbances. Blinding was achieved by running a strategic matched placebo parallel group. Co-primary outcome measures were the changes between baseline and end of the treatment period in sleep maintenance/efficiency as assessed by polysomnography and the Parkinson's Disease Sleep Scale Version 2 (PDSS-2) score.A total of 20 of 30 patients were randomized to rasagiline (mean ± SD age, 69.9 ± 6.9 years; 10 male; Hoehn-Yahr stage, 1.9 ± 0.8). Compared with baseline, sleep maintenance was significantly increased at the end of the treatment period (relative change normalized to baseline, +16.3 ± 27.9%; P = 0.024, paired two-sided t-test) and a positive trend for sleep efficiency was detected (+12.1 ± 28.6%; P = 0.097). Treatment with rasagiline led to significantly decreased wake time after sleep onset, number of arousals, percentage of light sleep and improved daytime sleepiness as measured by the Epworth Sleepiness Scale. We did not observe changes in the co-primary endpoint PDSS-2 score, and no correlations of polysomnographic sleep parameters or PDSS-2 score with motor function (Unified Parkinson's Disease Rating Scale motor score). Rasagiline was well tolerated with no unexpected adverse events.In patients with PD with sleep disturbances, rasagiline showed beneficial effects on sleep quality as measured by polysomnography. These effects were probably not related to motor improvement or translated into improved overall sleep quality perception by patients.

Keyword(s): Aged (MeSH) ; Aged, 80 and over (MeSH) ; Double-Blind Method (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Indans: therapeutic use (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Neuroprotective Agents: therapeutic use (MeSH) ; Parkinson Disease: complications (MeSH) ; Polysomnography: drug effects (MeSH) ; Sleep: drug effects (MeSH) ; Sleep Wake Disorders: complications (MeSH) ; Sleep Wake Disorders: drug therapy (MeSH) ; Treatment Outcome (MeSH) ; Indans ; Neuroprotective Agents ; rasagiline

---

Contributing Institute(s):

1. Clinical Dementia Research Rostock /Greifswald (Clinical Dementia Research Rostock /Greifswald ; AG Teipel)
2. Non-motor symptoms in Parkinson's disease (AG Storch ; AG Storch 2 Rostock)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; IF >= 5 ; JCR ; SCOPUS ; Web of Science Core Collection

---